A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations
Sign Up to like & getrecommendations! Published in 2021 at "Cell Reports"
DOI: 10.1016/j.celrep.2021.109433
Abstract: The novel betacoronavirus SARS-CoV-2 causes a form of severe pneumonia disease, termed COVID-19. To develop human neutralizing anti-SARS-CoV-2 antibodies, antibody gene libraries from convalescent COVID-19 patients were constructed and recombinant antibody fragments (scFv) against the… read more here.
Keywords: covid patients; antibody; ste90 c11; sars cov ... See more keywords